The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations.
- DOI
- 10.1080/14737140.2026.2630025
- Published
- 2026 Aug
- Container
- Expert review of anticancer therapy
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14737140.2026.2630025,
title = {The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations.},
author = {Lin S and Wang X and Yang L and Luo S and Huang X and Weng X and Xu X},
year = {2026},
journal = {Expert review of anticancer therapy},
doi = {10.1080/14737140.2026.2630025},
url = {https://doi.org/10.1080/14737140.2026.2630025}
}RIS
TY - JOUR TI - The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations. AU - Lin S AU - Wang X AU - Yang L AU - Luo S AU - Huang X AU - Weng X AU - Xu X PY - 2026 JO - Expert review of anticancer therapy DO - 10.1080/14737140.2026.2630025 UR - https://doi.org/10.1080/14737140.2026.2630025 ER -
APA
S, L., X, W., L, Y., S, L., X, H., X, W., & X, X. (2026). The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations.. Expert review of anticancer therapy. https://doi.org/10.1080/14737140.2026.2630025
Source records
- pubmed · retrieved 2026-09-27T16:30:22.104Z